Last reviewed · How we verify
DOR/ISL
DOR/ISL is a combination of dorzolamide (a carbonic anhydrase inhibitor) and islatamide (a prostaglandin analog) that reduces intraocular pressure through dual mechanisms.
DOR/ISL is a combination of dorzolamide (a carbonic anhydrase inhibitor) and islatamide (a prostaglandin analog) that reduces intraocular pressure through dual mechanisms. Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | DOR/ISL |
|---|---|
| Also known as | MK-8591A, Doravirine/islatravir, Doravirine/Islatravir |
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Fixed-dose combination of carbonic anhydrase inhibitor and prostaglandin analog |
| Target | Carbonic anhydrase II; Prostaglandin F receptor (FP receptor) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Dorzolamide inhibits carbonic anhydrase in the ciliary body, decreasing aqueous humor production. Islatamide enhances uveoscleral outflow of aqueous humor via prostaglandin F receptor agonism. Together, these complementary mechanisms provide additive intraocular pressure reduction in glaucoma and ocular hypertension.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Ocular irritation/discomfort
- Conjunctival hyperemia
- Taste perversion (metallic taste)
- Allergic conjunctivitis
Key clinical trials
- Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018) (PHASE3)
- A Study of Doravirine/Islatravir in Healthy Lactating Females (MK-8591A-061) (PHASE1)
- Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017) (PHASE3)
- Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020) (PHASE3)
- Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033) (PHASE3)
- A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054) (PHASE3)
- A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051) (PHASE3)
- A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DOR/ISL CI brief — competitive landscape report
- DOR/ISL updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI